Oral · GLP-1 agonist
Noiiglutide / HS-20004 / SHR20004
9 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
9
Active
1
Recruiting
0
Completed
5
Sites
7
Countries
1
Endpoints
91
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
5
Phase 2
3
Phase 3
1
Trials by status
Active, not recruiting
1
Completed
5
Unknown
3
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
40
Glycemic / diabetes
32
Weight & body composition
10
Other (unclassified)
6
Cardiometabolic biomarkers
3
Most-measured metrics
Top 20 metrics across this asset's endpoints
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
9 of 9